logo
Tried intermittent fasting with your phone? Here's why digital fasting may help your eyes, mind and body

Tried intermittent fasting with your phone? Here's why digital fasting may help your eyes, mind and body

Mint2 days ago
On a lazy day, while scrolling social media posts mindlessly on my phone, I stumbled upon one post that made me rethink what I was doing. It was a post by Indian actor Kunal Kapoor. He reminded me the importance of reading more and scrolling less in a world of digital excess. He emphasized on spending more time with people offline than online. And he suggested intermittent fasting with the phone: 9 hours on, 15 hours off! Digital fasting seems to be emerging as a wellness mantra, especially to beat the mental fatigue, eye strain and lack of motion that it leads to. It may seem difficult to think of, but making a conscious effort to take screen breaks can be helpful, says an expert.
Digital fasting refers to the conscious and periodic break from digital screen use—phones, computers, tablets, and TVs—to rest the eyes and reduce mental fatigue.
"It's a preventive approach to mitigate digital eye strain (DES), also known as 'computer vision syndrome'. With screen use surging due to hybrid work, online learning, and entertainment, digital fasting helps reset the visual system, prevent accommodative stress, dry eye, and preserve long-term ocular comfort and function," Dr Pooja Prabhu, Consultant Ophthalmologist, Dr Agarwals Eye Hospital, Bengaluru, tells Health Shots.
With hybrid work models becoming almost a norm in corporate jobs, people spend long hours watching a screen. For adults with work-related or children with academic-related screen demands, managing screen exposure through structured break and eye ergonomics is crucial. That's where digital fasting comes into play.
"Around 8–10 hours of screen time per day is common, but it must be counterbalanced with good practices like the '20-20-20 rule', appropriate lighting, and hydration," adds Dr Prabhu.
Otherwise, prolonged screen use has both short-term and long-term side effects.
* Dry eyes (reduced blinking)
* Blurred or fluctuating vision
* Persistent dry eye syndrome
* Progression of myopia (nearsightedness), especially in children
* Visual fatigue affecting productivity and concentration
* Potential disruption of circadian rhythms due to blue light exposure, affecting sleep and overall health
Taking regular breaks from screens may significantly reduce digital eye strain symptoms.
"Regular breaks allow the eye muscles to relax, replenish the tear film, and relieve visual fatigue. Even short, 1–2 minute breaks every 20–30 minutes can make a significant difference," says the expert.
You may notice improvement within 24 to 72 hours of reduced screen time, especially in symptoms like dryness, eye fatigue, and headaches. For chronic cases, especially with dry eye syndrome, it may take a few weeks of consistent digital fasting and supportive care (like lubricating drops) to see full resolution.
Your screen time before bed also matters when it comes to digital eye strain. The doctor suggests a minimum of 1 hour of screen-free time before bed is ideal, and 2 hours is even better!
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

India records 18 lakh new brain stroke cases every year, nationwide campaign launched
India records 18 lakh new brain stroke cases every year, nationwide campaign launched

The Hindu

time42 minutes ago

  • The Hindu

India records 18 lakh new brain stroke cases every year, nationwide campaign launched

India records a brain stroke every 20 seconds, amounting to over 18 lakh new cases each year, yet public awareness about prevention and timely treatment remains low, said medical experts at the launch of the stroke awareness campaign titled 'Brain Stroke - Time to Act'. Speaking at the event, president of the Indian Stroke Association, stressed that brain stroke can happen to anyone, regardless of age, gender, education or economic background. She pointed out that while ischemic stroke is the most common type in India, only 1% of eligible patients receive IV thrombolysis, a clot-busting injection that can improve outcomes if administered within the golden window of 4.5 hours from symptom onset. 'Recognising symptoms like sudden weakness, difficulty speaking or loss of vision is crucial,' she said. Subhash Kaul, consultant neurologist at KIMS Hospital, Secunderabad, highlighted the need for timely intervention in cases of intracerebral haemorrhage, the deadliest form of stroke caused by brain bleeding. Public education plays a major role in early detection,' he noted. ISA treasurer Salil Uppal drew attention to the strong link between hypertension and stroke, revealing that one in four Indian adults suffers from high blood pressure. 'Hypertension is the single most important risk factor for strokes, particularly haemorrhagic ones,' he said, urging all adults above the age of 18 to check their blood pressure at least once a year. The campaign has been launched by the ISA in collaboration with the Indian Association of Physicians-Hyderabad Chapter and the Society for Emergency Medicine India.

Hospital Asset Tracking in India: Solving a ₹1.8 Crore Problem
Hospital Asset Tracking in India: Solving a ₹1.8 Crore Problem

Hans India

time3 hours ago

  • Hans India

Hospital Asset Tracking in India: Solving a ₹1.8 Crore Problem

A single Indian hospital can lose over ₹1.8 crore a year—not from surgeries gone wrong or billing disputes, but simply from patients getting lost and assets vanishing into storerooms. Nurses—India's most overworked frontline caregivers—can lose up to 60 minutes per shift just searching for equipment. These aren't isolated issues. And most hospitals have no system in place to fix them. The Hidden Costs Draining Indian Hospitals Rising costs in healthcare aren't always about advanced machinery or doctor salaries. Many of India's private hospitals are silently losing lakhs every year because of invisible inefficiencies. Nurses waste up to 60 minutes per shift searching for equipment. Mobile medical devices like ECGs and oxygen cylinders go missing due to lack of tracking systems. Patients miss appointments after getting lost in multi-building campuses. Over-ordering of equipment happens due to poor visibility into what already exists. These aren't one-off problems—they are systemic leaks in the engine. How Much Time Do Nurses Lose Searching for Equipment? A report in Nursing Times shows that nurses lose 30–60 minutes per shift just finding medical equipment. For a 300-bed facility with 100 nurses, that adds up to over 50,000 hours of wasted skilled time each year. At a conservative ₹200/hour, that's ₹1 crore in annual productivity lost—not on patient care, but on chasing items like IV pumps or monitors. Now imagine recovering even 80% of that time through a real-time asset tracking system for hospitals. That's more healing, less hunting. Why Hospitals Keep Losing Expensive Equipment According to studies in both U.S. and Indian hospitals, 10–20% of mobile assets are lost or stolen over their lifecycle. In India, this often includes: Oxygen cylinders ECG machines Stretchers Patient monitors The Comptroller and Auditor General (CAG) found that in Kerala alone, medical equipment worth ₹7.28 crore was left unused due to mismanagement or lack of trained staff. And because hospitals can't track these assets, they over-order backup stock—leading to utilisation rates as low as 50%, compared to an industry ideal of 75–80%. This is a classic case of capital sitting idle while the system keeps spending. What is RTLS? Why Smart Hospitals in India Are Adopting It Real-Time Location Systems (RTLS) are indoor navigation and positioning systems that allow hospitals to: Track the location of assets and staff Guide patients through large campuses Reduce appointment no-shows Improve response time in emergencies However, most RTLS solutions require Wi-Fi, Bluetooth beacons, or expensive infrastructure—which makes them impractical for many Indian hospitals. Solution- A Hardware-Free RTLS System As hospitals search for indoor navigation systems that work without Bluetooth or Wi-Fi, or explore RTLS solutions tailored for Indian settings, one trend stands out: the shift toward hardware-free, softwar++++e-driven platforms. One such system gaining traction is Mapsted, which operates without external beacons or routers. Instead, it uses smartphone sensors and passive tags—making it more compatible with India's dense, multilingual, and often infrastructure-constrained hospital environments. Mapsted's RTLS works directly through smartphones and passive tags—making it: Cheaper to deploy Easier to maintain More suited to India's dense OPDs and multilingual patient base Hospitals using Mapsted's location-based platform have seen: Increased patient throughput Fewer missed appointments Reduction in lost equipment Over 2,000 staff hours saved annually Smart Navigation Is Not a Fancy Add-On—It's Infrastructure India's healthcare system is under pressure: rising medical costs, growing patient volumes, and a shrinking skilled workforce. To solve these challenges, hospitals must stop thinking of smart navigation and hospital asset tracking as 'nice to have' technologies. They are foundational tools for: Cutting operational losses Improving staff productivity Making better use of every rupee invested By choosing a solution like Mapsted's hardware-free RTLS system, hospitals don't just save money—they transform how healthcare works.

Zydus Life's plans for cancer biosimilar hit a legal hurdle
Zydus Life's plans for cancer biosimilar hit a legal hurdle

Time of India

time3 hours ago

  • Time of India

Zydus Life's plans for cancer biosimilar hit a legal hurdle

Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store